Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study

Lancet

Volumn 358, Issue 9291, 2001, Pages 1421-1423

  Van Oosterom, Allan T ^a   Judson, Ian ^b   Verweij, Jaap ^c   Stroobants, Sigrid ^a   Donato Di Paola, Eugenio ^d   Dimitrijevic, Sasa ^e   Martens, Marc ^a   Webb, Andrew ^b   Sciot, Raf ^a   Van Glabbeke, Martine ^d   Silberman, Sandra ^e   Nielsen, Ole S ^f  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d EORTC DATA CENTER   (Belgium)

^e NOVARTIS PHARMA AG   (Switzerland)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; IMATINIB; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; EDEMA; FEBRILE NEUTROPENIA; GASTROINTESTINAL CARCINOMA; GROWTH INHIBITION; HUMAN; METASTASIS; NAUSEA; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RASH; TOXICITY; TREATMENT OUTCOME; TUMOR GROWTH; VOMITING;

EID: 0035960428     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06535-7     Document Type: Article

References (13)

1. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
2. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcomas: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
3. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumours: Differences in clinical outcome and expression of multidrug resistance proteins
4. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal tumours and do not occur in leiomyomas or leiomyosarcomas
5. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
6. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
7. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
8. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
9. Abl tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
10. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumour
11. New guidelines to evaluate the response to treatment in solid tumours
12. 18Fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations